NCT03237780View on ClinicalTrials.gov

Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

July 20, 2018

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions
Locally Advanced Bladder Urothelial CarcinomaLocally Advanced Renal Pelvis Urothelial CarcinomaLocally Advanced Ureter Urothelial CarcinomaLocally Advanced Urethral Urothelial CarcinomaMetastatic Bladder Urothelial CarcinomaMetastatic Renal Pelvis Urothelial CarcinomaMetastatic Ureter Urothelial CarcinomaMetastatic Urethral Urothelial CarcinomaRecurrent Bladder Urothelial CarcinomaRecurrent Renal Pelvis Urothelial CarcinomaRecurrent Ureter Urothelial CarcinomaRecurrent Urethral Urothelial CarcinomaStage III Bladder Cancer AJCC v8Stage III Renal Pelvis Cancer AJCC v8Stage III Ureter Cancer AJCC v8Stage III Urethral Cancer AJCC v8Stage IV Bladder Cancer AJCC v8Stage IV Renal Pelvis Cancer AJCC v8Stage IV Ureter Cancer AJCC v8Stage IV Urethral Cancer AJCC v8Unresectable Bladder Urothelial CarcinomaUnresectable Renal Pelvis Urothelial CarcinomaUnresectable Ureter Urothelial CarcinomaUnresectable Urethral Urothelial Carcinoma
Interventions
DRUG

Atezolizumab

Given IV

PROCEDURE

Biopsy Procedure

Undergo biopsy

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Computed Tomography with Contrast

Undergo CT scan

DRUG

Eribulin Mesylate

Given IV

Trial Locations (21)

15232

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

35233

University of Alabama at Birmingham Cancer Center, Birmingham

64064

University of Kansas Cancer Center - Lee's Summit, Lee's Summit

64116

University of Kansas Cancer Center at North Kansas City Hospital, North Kansas City

64154

University of Kansas Cancer Center - North, Kansas City

66160

University of Kansas Cancer Center, Kansas City

66205

University of Kansas Clinical Research Center, Fairway

University of Kansas Hospital-Westwood Cancer Center, Westwood

66210

University of Kansas Cancer Center-Overland Park, Overland Park

66211

University of Kansas Hospital-Indian Creek Campus, Overland Park

90020

Keck Medicine of USC Koreatown, Los Angeles

90033

Los Angeles General Medical Center, Los Angeles

USC / Norris Comprehensive Cancer Center, Los Angeles

90621

Keck Medicine of USC Buena Park, Buena Park

91010

City of Hope Comprehensive Cancer Center, Duarte

91105

Keck Medical Center of USC Pasadena, Pasadena

91786

City of Hope Upland, Upland

92618

City of Hope at Irvine Lennar, Irvine

92663

USC Norris Oncology/Hematology-Newport Beach, Newport Beach

92868

UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange

95817

University of California Davis Comprehensive Cancer Center, Sacramento

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH